文献速递神经免疫

COVID-19感染对多发性硬化患者症状严重程度与残疾的影响

Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis.
PubMed 文献 · Neurology · 2024-12-23

本研究采用对照中断时间序列设计,基于北美多发性硬化研究委员会登记库的纵向数据,评估COVID-19感染与多发性硬化症状和残疾轨迹的关系。结果显示,COVID-19感染与症状严重程度或残疾的即刻变化无关,也未改变中位随访18个月内的结局轨迹。

要点

  • COVID-19感染后症状严重程度总分的即刻变化为0.41(95%CI -0.13至0.94),组间无差异。
  • 感染前后症状评分随时间的变化在感染组与未感染组之间均无差异。
  • 残疾结局与症状严重程度结果相似,感染未改变其轨迹。

核心结论

  • 采用中断时间序列设计发现,COVID-19感染与症状严重程度或残疾的即刻变化无关,也未改变这些结局在中位随访18个月内的轨迹。

研究设计与样本

  • 对照中断时间序列(准实验设计),使用北美多发性硬化研究委员会登记库的纵向数据。
  • 2023年春季调查应答率为67.3%,4,787名参与者完成了COVID-19相关问题。
  • COVID-19感染队列包括796名在索引调查前后各有至少3次调查的参与者;未感染队列包括1,534名报告过去6个月无COVID-19或其他感染者,其中1,336人具备所需的前后调查次数。

主要发现

  • 调整参与者特征后,COVID-19队列和未感染队列的症状评分(SMSS)随时间轻度升高,感染前(0.005,95%CI -0.025至0.035)和感染后(-0.0002,95%CI -0.014至0.014)的随时间变化在组间均无差异。
  • COVID-19感染对症状评分总分的即刻影响在感染队列内很小,且组间无差异(0.41,95%CI -0.13至0.94)。
  • 残疾结局(PDDS)的结果与症状严重程度相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结果可能不能推广至年轻的多发性硬化患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Infections, including infection with SARS-CoV-2 (COVID-19), could alter the course of multiple sclerosis (MS). Previous studies assessing the effects of COVID-19 on MS outcomes were small and had discordant findings. The study objective was to evaluate the association of COVID-19 infection with changes in the trajectory of MS symptoms and disability. METHODS: We used a controlled interrupted time series (ITS), a quasiexperimental study design using longitudinal data from the North American Research Committee on Multiple Sclerosis Registry. Participants who completed at least 3 surveys before and after their index survey were identified. Exposure of interest was COVID-19 infection based on confirmed diagnosis using an at-home or laboratory test, as reported by the participant. Symptoms were measured using the SymptoMScreen (SMSS), a self-report measure of symptom severity across 12 domains common in MS. Disability was measured using PDDS. Segmented regression was used to compare changes in outcomes over time between cohorts, before and after the exposure (COVID-19 infection). RESULTS: The spring 2023 survey response rate was 67.3%, and 4,787 participants completed the COVID-19 questions. Of those participants, 2,106 (44.0%) reported ever having confirmed COVID-19. The COVID-19 infection cohort included 796 participants with ≥3 surveys both before and after index survey. The uninfected cohort included 1,534 participants (32.0%) who reported never having COVID-19 nor other infections in the previous 6 months, of whom 1,336 had the requisite number of presurveys and postsurveys. After adjusting for participant characteristics, the SMSS score increased nominally over time in the COVID-19 and uninfected cohorts and this change over time did not differ between cohorts either before (0.005, 95% CI -0.025 to 0.035) or after (-0.0002, 95% CI -0.014 to 0.014) COVID-19 infection. The immediate effect of COVID-19 infection on the SMSS total score was minimal within the COVID-19 cohort and did not differ between cohorts (0.41, 95% CI -0.13 to 0.94). Findings were similar for disability. DISCUSSION: Our study using an ITS design found that COVID-19 infection was not associated with immediate changes in symptom severity or disability, nor did it change the trajectories of these outcomes over a median follow-up of 18 months. Although results may not generalize to younger people with MS, these findings enhance our general understanding of the consequences of infection in people with MS.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Salter A, Lancia S, Cutter GR, et al. Effects of COVID-19 Infection on Symptom Severity and Disability in Multiple Sclerosis. Neurology. 2024. PMID: 39715473. doi:10.1212/WNL.0000000000210149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。